World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
113
Citations
55934
World Ranking
4885
National Ranking
2646

Overview

Andrew L. Kung is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research activity focuses primarily on medicine and biochemistry, genetics, and molecular biology, with notable contributions in molecular biology, cancer research, oncology, hematology, and genetics.

The scientist's work covers a range of topics, including:

  • Cancer Genomics and Diagnostics
  • Hematopoietic Stem Cell Transplantation
  • Acute Myeloid Leukemia Research
  • Sarcoma Diagnosis and Treatment
  • Neuroblastoma Research and Treatments
  • Acute Lymphoblastic Leukemia research
  • CAR-T cell therapy research

Among recent publications, Andrew L. Kung contributed to:

  • "An expanded universe of cancer targets," 2021, Cell
  • "COVID-19 in Children With Cancer in New York City," 2020, JAMA Oncology
  • "Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors," 2021, Nature Cancer
  • "STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma," 2021, Cancer Cell
  • "Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers," 2022, Nature Communications

The frequent co-authors who have collaborated extensively with Andrew L. Kung include:

  • Filemon S. Dela Cruz
  • Daoqi You
  • Neerav Shukla
  • Barbara Spitzer
  • Gunes Gundem

Andrew L. Kung's research has been disseminated through various publication venues, with the following being the most frequent:

  • Cancer Research
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Journal of Clinical Oncology
  • Cytotherapy
  • Blood Advances

Best Publications

  • BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

    Jake E. Delmore;Ghayas C. Issa;Madeleine E. Lemieux;Peter B. Rahl

  • Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

    Ellen Weisberg;Paul W. Manley;Werner Breitenstein;Josef Brüggen

  • Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix

    Loren D. Walensky;Andrew L. Kung;Andrew L. Kung;Iris Escher;Thomas J. Malia;Thomas J. Malia

  • Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing

    Chryssa Kanellopoulou;Stefan A. Muljo;Andrew L. Kung;Shridar Ganesan

  • Role of T-bet in Commitment of TH1 Cells Before IL-12-Dependent Selection

    Alan C. Mullen;Frances A. High;Anne S. Hutchins;Hubert W. Lee

  • Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor

    Scott R. Daigle;Edward J. Olhava;Carly A. Therkelsen;Christina R. Majer

  • MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L

    Kathrin M. Bernt;Nan Zhu;Amit U. Sinha;Sridhar Vempati

  • Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF

    Rizwan Haq;Jonathan Shoag;Pedro Andreu-Perez;Satoru Yokoyama;Satoru Yokoyama

  • Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

    Bjoern Chapuy;Michael R. McKeown;Charles Y. Lin;Stefano Monti

  • Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

    Constantine S Mitsiades;Nicholas S Mitsiades;Nicholas S Mitsiades;Ciaran J McMullan;Vassiliki Poulaki;Vassiliki Poulaki

  • A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors

    Joshua B. Rubin;Andrew L. Kung;Robyn S. Klein;Jennifer A. Chan

  • Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

    Alexandre Puissant;Stacey M. Frumm;Gabriela Alexe;Christopher F. Bassil

  • SCF FBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction

    Hiroyuki Inuzuka;Shavali Shaik;Ichiro Onoyama;Darning Gao

  • Suppression of tumor growth through disruption of hypoxia-inducible transcription.

    Andrew L. Kung;Stream Wang;Jeffery M. Klco;William G. Kaelin

  • NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis

    Jonathan D. Brown;Charles Y. Lin;Qiong Duan;Qiong Duan;Gabriel Griffin

  • Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

    Loredana Santo;Teru Hideshima;Andrew L. Kung;Jen-Chieh Tseng

  • Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway.

    Andrew L. Kung;Sonya D. Zabludoff;Sonya D. Zabludoff;Steven J. Freedman;Steven J. Freedman

  • H3K79 Methylation Profiles Define Murine and Human MLL-AF4 Leukemias

    Andrei V. Krivtsov;Zhaohui Feng;Madeleine E. Lemieux;Joerg Faber

  • p300/MDM2 Complexes Participate in MDM2-Mediated p53 Degradation

    Steven R Grossman;Marco Perez;Andrew L Kung;Michael Joseph

  • Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

    Yazan Alsayed;Hai Ngo;Judith Runnels;Xavier Leleu

Frequent Co-Authors

James E. Bradner
James E. Bradner Amgen (United States)
Scott A. Armstrong
Scott A. Armstrong Harvard University
James D. Griffin
James D. Griffin Harvard University
Richard Stone
Richard Stone Harvard University
Scott J. Rodig
Scott J. Rodig Harvard University
David M. Livingston
David M. Livingston Harvard University
Ellen Weisberg
Ellen Weisberg Harvard University
Todd R. Golub
Todd R. Golub Harvard University
Constantine S. Mitsiades
Constantine S. Mitsiades Harvard University
Paul G. Richardson
Paul G. Richardson Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in a medical career but looking for flexible or expedited routes, there are several online programs to consider. For nurses aiming to quickly reach the highest level of clinical practice, the shortest dnp programs offer accelerated pathways to earn your Doctor of Nursing Practice degree online.

Cost is an important factor for many students. If affordability is your priority, the cheapest online dnp programs can make pursuing a doctorate more accessible and achievable.

Those seeking to enter the workforce quickly might explore the fast lpn program, an option designed for rapid entry into practical nursing with minimal time commitment.

For advanced practice in mental health, professionals can consider pmhnp online programs, which prepare nurses for a specialized and in-demand role as psychiatric-mental health nurse practitioners.

These online degrees and career pathways offer flexibility, speed, and accessibility, making them excellent alternatives or complements to traditional medical education in the USA.

Best Scientists Citing Andrew L. Kung

Trending Scientists